Payer's maximum price per patient from a cost-effectiveness threshold

Gives the highest price per patient at which a payer that funds technologies with an incremental cost-effectiveness ratio at or below the threshold k still funds the product. At this price the ratio equals k and the incremental net monetary benefit (HE-FM-NMB-002) is zero. In bargaining terms it is the payer's walk-away price, the top of the range over which the price is negotiated.

Signature

p_bar = k * Delta_E - Delta_C_o
Inputs
InputsDefinitionUnit
kCost-effectiveness threshold the payer applies to funding decisionscurrency per QALY
Delta_EIncremental QALYs per patient from the product compared with current careQALYs per patient
Delta_C_oIncremental cost per patient other than the product's price, such as administration costscurrency per patient
Output
p_barHighest price per patient at which the product's incremental cost-effectiveness ratio does not exceed the thresholdcurrency per patient

Function

Nash bargaining surplus-division function for negotiated health care prices

Maps the payoffs two negotiating parties obtain from each feasible agreement, their disagreement payoffs and their relative bargaining power to the agreement that maximises the weighted product of their gains over disagreement. In a price negotiation between a payer and a manufacturer the feasible agreements are prices from the manufacturer's reservation price up to the payer's maximum price, and the function returns the price that splits the surplus between them in proportion to their bargaining weights. A weight of one half gives Nash's original symmetric solution. The payer's maximum price can come from a cost-effectiveness threshold (HE-FM-BARG-002), the manufacturer's weight from the parties' patience in an alternating-offers model (HE-FM-BARG-003), and an outside option changes the result only when it binds (HE-FM-BARG-004).

Try this function

Implementations

  • Excel

    Payer's maximum price from a threshold in one cell

    Excel multiplies the threshold by the incremental QALYs and subtracts the other incremental costs, using named cells per patient.

    =Threshold*IncQALYs-OtherIncCost

Assumptions

  • One course per patient priced as a unit

    Each patient receives one course, so the price, the QALY gain and the other costs are all per patient. If a course is supplied in several packs, the maximum price per pack is p_bar divided by the number of packs per patient.

  • Threshold that reflects the health displaced by spending

    The payer funds the product when the ratio is at or below k, Delta_E is above zero, and k represents the health displaced by extra spending. If k is above the value of the health displaced, a price at p_bar displaces more health than the product adds.

Worked examples

  • Maximum price at £20,000 per QALY for an illustrative treatment

    A gain of 0.5 QALYs per patient, other incremental costs of £2,000 and a threshold of £20,000 per QALY give a maximum price of £8,000 per patient, as in the article. With a reservation price of £1,000 the surplus to divide is £7,000 per patient.

    k = 20000; Delta_E = 0.5; Delta_C_o = 2000; p_bar = 8000
  • Maximum price at an illustrative £30,000 per QALY

    For the same treatment a threshold of £30,000 per QALY raises the maximum price to £13,000 per patient, so a higher threshold widens the range over which the price is bargained.

    k = 30000; Delta_E = 0.5; Delta_C_o = 2000; p_bar = 13000

Common errors

  • Leaving other incremental costs out of the maximum price

    Multiplying the threshold by the QALY gain alone gives £10,000 rather than £8,000 per patient. At £10,000 the ratio is £24,000 per QALY, above the £20,000 threshold, so the payer would not fund the product at that price.

  • Applying the maximum price per patient to each pack

    When a course is supplied in several packs, setting each pack at p_bar multiplies the cost per patient. With four packs per course and a maximum of £8,000 per patient, the maximum price per pack is £2,000.

Sources

  • Claxton and colleagues on the price at which the ratio equals the threshold

    Claxton K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, Walker S, Sculpher MJ. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ. 2008;336(7638):251-254. Box 1, in which a price at which the ratio equals the threshold leaves net health benefit to the NHS at zero and a higher price is not cost effective, and the text noting that such a price passes all the benefit of the innovation to the manufacturer as revenue.

    View source →

  • Berdud and colleagues on the threshold as the payer's maximum ratio

    Berdud M, Ferraro J, Towse A. A theory on ICER pricing and optimal levels of cost-effectiveness thresholds: a bargaining approach. Frontiers in Health Services. 2023;3:1055471. Section 2.3, in which the payer commits to a threshold before bargaining and, when the developer holds all the bargaining power, the agreed ratio equals the health system's maximum ability to pay.

    View source →

Canonical Identity

Stable URI · Machine-readable · Resolvable · CC BY 4.0